Tetanus medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Tetanus is a medical emergency. Medical therapy includes hospitalization, immediate treatment with human tetanus immune globulin (TIG) (or equine antitoxin if human immune globulin is not available), a tetanus toxoid booster, agents to control muscle spasm, aggressive wound care, and antimicrobial therapy. Mechanical ventilation and agents to control autonomic nervous system instability may be required among patients with severe disease.[1]
Medical Therapy
The medical therapy for tetanus may include:[2][3][4][5][6]
- 1. General measures [1]
- Preferred regimen: Patients should be placed in a quiet shaded area and protected from tactile and auditory stimulation as much as possible; All wounds should be cleaned and debrided as indicated
- 2. Immunotherapy
- Preferred regimen: Human TIG 500 units IV/IM as soon as possible AND Age-appropriate TT-containing vaccine, 0.5 cc IM at a separate site
- Note: patients without a history of primary TT vaccination should receive a second dose 1β2 months after the first dose and a third dose 6β12 months later
- 3. Antibiotic treatment[7]
- Preferred regimen: Metronidazole 500 mg IV/PO q6h OR Penicillin G 100,000β200,000 IU/kg/day IV, administered in 2β4 divided doses
- Alternative regimen: Tetracyclines OR Macrolides OR Clindamycin OR Cephalosporins OR Chloramphenicol
- 4. Muscle spasm control
- Preferred regimen: Diazepam 5 mg IV OR Lorazepam 2 mg IV titrating to achieve spasm control without excessive sedation and hypoventilation
- Alternative regimen (1): Magnesium sulphate 5 g (or 75mg/kg) IV loading dose, then 2β3 g per hour until spasm control is achieved Β± Benzodiazepines
- Note: Monitor patellar reflex as areflexia (absence of patellar reflex) occurs at the upper end of the therapeutic range (4mmol/L). If areflexia develops, dose should be decreased
- Alternative regimen (2): Baclofen OR Dantrolene 1β2 mg/kg IV/PO q4h OR Bromocriptine OR Amantadine
- Alternative regimen (3): Barbiturates 100β150 mg q1-4h by any route
- Alternative regimen (4): Chlorpromazine 50β150 mg IM q4β8h
- Pediatric regimen: Lorazepam 0.1β0.2 mg/kg IV q2β6h, titrating upward as needed; Barbiturates 6β10 mg/kg in children by any route; Chlorpromazine 4β12 mg IM every q4β8h
- Note: As for Benzodiazepines, large amounts may be required (up to 600 mg/day); oral preparations could be used but must be accompanied by careful monitoring to avoid respiratory depression or arrest
- 5. Autonomic dysfunction control
- 6. Airway/respiratory control
- Note: Drugs used to control spasm and provide sedation can result in respiratory depression. If spasm, including laryngeal spasm, is impeding or threatening adequate ventilation, mechanical ventilation is recommended when possible. Early tracheostomy is preferred as endotracheal tubes can provoke spasm and exacerbate airway compromise.
References
- β 1.0 1.1 “Current recommendations for treatment of tetanus during humanitarian emergencies”.
- β Farrar JJ, Yen LM, Cook T, Fairweather N, Binh N, Parry J; et al. (2000). “Tetanus”. J Neurol Neurosurg Psychiatry. 69 (3): 292β301. PMCΒ 1737078. PMIDΒ 10945801.
- β Lalli G, Gschmeissner S, Schiavo G (2003). “Myosin Va and microtubule-based motors are required for fast axonal retrograde transport of tetanus toxin in motor neurons”. J Cell Sci. 116 (Pt 22): 4639β50. doi:10.1242/jcs.00727. PMIDΒ 14576357.
- β Rummel A, Bade S, Alves J, Bigalke H, Binz T (2003). “Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity”. J Mol Biol. 326 (3): 835β47. PMIDΒ 12581644.
- β Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR; et al. (1992). “Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin”. Nature. 359 (6398): 832β5. doi:10.1038/359832a0. PMIDΒ 1331807.
- β Caccin P, Rossetto O, Rigoni M, Johnson E, Schiavo G, Montecucco C (2003). “VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes”. FEBS Lett. 542 (1β3): 132β6. PMIDΒ 12729912.
- β http://www.who.int/diseasecontrol_emergencies/who_hse_gar_dce_2010_en.pdf
Β© 2026 MyEClinic β IFTM Institut fΓΌr Telematik in der Medizin GmbH
